Arsenic trioxide (Trisenox®) in patients with relapsed or refractory multiple myeloma (MM):: Final report of a phase II clinical study.

被引：0
|
作者：
Hussein, MA
Mason, J
Saleh, MN
Rifkin, RM
Ravandi, F
机构：
[1] Cleveland Clin Canc Ctr, Multiple Myeloma Res Program, Cleveland, OH USA
[2] Scripps Clin, San Diego, CA USA
[3] Georgia Canc Specialists, Atlanta, GA USA
[4] Rocky Mt Canc Ctr, Denver, CO USA
[5] Univ Illinois, Chicago, IL USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5138
引用
收藏
页码：393B / 393B
页数：1
相关论文
共 50 条
  • [1] A phase II clinical study of arsenic trioxide (ATO) in patients(pts) with relapsed or refractory multiple myeloma (MM); a preliminary report
    Hussein, MA
    Mason, J
    Ravandi, F
    Rifkin, RM
    BLOOD, 2001, 98 (11) : 378A - 378A
  • [2] Arsenic trioxide (Trisenox® ATO), ascorbic acid (AA) and dexamethasone (Dex) pulses (TAD) for relapsed refractory progressive multiple myeloma (MM) patients (pts);: a final report
    Abou-Jawde, RM
    Reed, J
    Kelly, M
    Platt, L
    Karam, MA
    Kovak, MR
    Srkalovic, G
    Hussein, MA
    BLOOD, 2004, 104 (11) : 665A - 665A
  • [3] Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma
    Hussein, MA
    Saleh, M
    Ravandi, F
    Mason, J
    Rifkin, RM
    Ellison, R
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (04) : 470 - 476
  • [4] A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients With Relapsed/Refractory Multiple Myeloma
    Held, Lauren A.
    Rizzieri, David
    Long, Gwynn D.
    Gockerman, Jon P.
    Diehl, Louis F.
    De Castro, Carlos M.
    Moore, Joseph O.
    Horwitz, Mitchell E.
    Chao, Nelson J.
    Gasparetto, Cristina
    CANCER INVESTIGATION, 2013, 31 (03) : 172 - 176
  • [5] Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma
    Wu, Ka Lung
    Beksac, Meral
    van Droogenbroeck, Jan
    Amadori, Sergio
    Zweegman, Sonja
    Sonneveld, Pieter
    HAEMATOLOGICA, 2006, 91 (12) : 1722 - 1723
  • [6] Trisenox® (arsenic trioxide, ATO) in patients (pts) with myelodysplastic syndromes (MDS):: Preliminary findings in a phase II clinical study.
    List, AF
    Schiller, GJ
    Mason, J
    Douer, D
    Paradise, C
    BLOOD, 2002, 100 (11) : 790A - 790A
  • [7] A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma
    Zhao, Hongli
    Sun, Guoxun
    Kong, Desheng
    Zhang, Yujing
    Shi, Wudan
    Zhao, Mingming
    Hong, Luojia
    Qiao, Zhenkui
    MEDICAL ONCOLOGY, 2015, 32 (03)
  • [8] A phase II study of arsenic trioxide in patients with relapsed or refractory malignant lymphoma
    Hongli Zhao
    Guoxun Sun
    Desheng Kong
    Yujing Zhang
    Wudan Shi
    Mingming Zhao
    Luojia Hong
    Zhenkui Qiao
    Medical Oncology, 2015, 32
  • [9] Trisenox® (arsenic trioxide) in patients with myelodysplastic syndromes (MDS):: Preliminary results of a phase I/II study.
    Vey, N
    Dreyfus, F
    Guerci, A
    Fenaux, P
    Dombret, H
    Burnett, AK
    Bosly, A
    Feremans, W
    Bowen, DT
    Heiskala, M
    BLOOD, 2004, 104 (11) : 401A - 402A
  • [10] Trisenox® (Arsenic trioxide) in patients (pts) with myelodysplastic syndromes (MDS):: Preliminary results of a phase II study.
    Vey, N
    Blaise, D
    Damaj, G
    Gastaut, JA
    Garzon, F
    Paradise, C
    Panning, L
    BLOOD, 2002, 100 (11) : 342B - 342B
12345